NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA Leiden, the Netherlands, 25 April 2012 – OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), announces today that it has successfully completed an equity raising with € 3 million net proceeds through a private placement of 7.9 million shares at an offer price of € 0.40 per share with OGBB A. van Herk B.V. (the “Private Placement”). OctoPlus intends to use the proceeds of the Private Placement for working capital purposes and to invest in projects with financial upside potential. The shares will be issued in two tranches. The first tranche of 3 million shares (the “First Tranche Shares”) will be issued today, while the second tranche of 4.9 million shares (the “Second Tranche Shares”) will be issued after and subject to the Executive Board of OctoPlus having been delegated the authority to issue additional shares, by the Annual General Meeting of Shareholders which is scheduled on 13 June 2012. The agenda and the explanatory notes of this meeting will be published shortly on the website of OctoPlus. Jan Egberts, CEO of OctoPlus, says: “We are very pleased with the confidence that Van Herk has shown in OctoPlus and our management team. We are looking forward to work together to further strengthen and expand on our key strategic initiatives.” As a result of the Private Placement, the total number of shares outstanding will increase to 47,778,974 shares following the issuance of the First Tranche Shares and to 52,673,974 shares following the issuance of the Second Tranche Shares. The First Tranche Shares are expected to be admitted to listing and trading on Euronext Amsterdam by NYSE Euronext (“Euronext Amsterdam”) on or about 27 April 2012. Contact For further information about OctoPlus and the Private Placement, please contact Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071 or send an e-mail to Investor Relations at VE@bpgbcyhf.ay About OctoPlus OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on our proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus also focuses on the development of long-acting, controlled release versions of known protein therapeutics, peptides and small molecules, including specialty generics. The clinically most advanced product incorporating our technology is Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and has recently completed Phase IIb clinical studies with superior clinical data versus current treatment. In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients. OctoPlus is listed on Euronext Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl #### This announcement is not an offer to sell or a solicitation of any offer to buy the securities of OctoPlus (the “Securities”) in the United States or in any other jurisdiction. The shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States or to or for the account or benefit of, U.S. persons (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or an exemption from such registration is available. No public offering of Securities of OctoPlus is being made in the United States. This announcement does not constitute a prospectus. This document may contain certain forward-looking statements relating to the business, financial performance and results of the Company and the industry in which it operates. These statements are based on OctoPlus N.V.’s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words “expect”, “anticipate”, “predict”, “estimate”, “project”, “plan”, “may”, “should”, “would”, “will”, “intend”, “believe” and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version. Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to U.S. persons. This announcement is not a prospectus and does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction. The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from, or to or for the account of U.S. persons (as such term is defined in Regulation S under the Securities Act) or transaction not subject to, the registration requirements of the Securities Act. This announcement is not an offer to sell or a solicitation of any offer to buy the securities of OctoPlus (the “Securities”) in the United States or in any other jurisdiction. This announcement does not constitute a prospectus.